Cancer
ARTEMIDE-Lung04
Trial overview
Description
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
Study details
For detailed information on this trial, please click here
Trial status
Due to open March 2026
Principal Investigator
Dr Omar Khan
Location
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.